{"product_id":"oakstone-intensive-review-of-nephrology-2025","title":"Oakstone Intensive Review of Nephrology 2025","description":"\u003ch3\u003eOakstone Intensive Review of Nephrology 2025\u003c\/h3\u003e\n\u003cstrong\u003e Include: 94 videos + 2 pdfs, size: 26.2 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: clinical and academic nephrologists, internists, pediatricians, and primary care physicians\/trainees\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003ch3\u003e\u003cstrong\u003eNew Release! Unmatched Board Prep and Nephrology Update\u003c\/strong\u003e\u003c\/h3\u003e\u003cbr\u003eThe \u003cem\u003eIntensive Review of Nephrology\u003c\/em\u003e is an advanced online video course from School, designed to deliver an in-depth update across all areas of nephrology. Through 70+ expert-led lectures and case discussions, you’ll gain essential, evidence-based knowledge for optimizing diagnosis, treatment, and patient outcomes.\u003cbr\u003e\u003cbr\u003eThis continuing medical education program is ideal for clinicians seeking a comprehensive review and physicians preparing for ABIM certification or recertification. Expert faculty evidence-driven strategies for managing common and complex renal conditions. Highlights include:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eGenetic testing for improved diagnosis, prognosis and therapy selection\u003c\/li\u003e\n\u003cli\u003eIntroduction to point-of-care ultrasound: fundamentals for optimal image acquisition and accurate interpretation\u003c\/li\u003e\n\u003cli\u003ePhysical exam of the dialysis access\u003c\/li\u003e\n\u003cli\u003eFurther expansion of the roles of SGLT2i and finerenone in diabetic and non-diabetic kidney disease\u003c\/li\u003e\n\u003cli\u003eNew insights in immunology and the pathogenesis of glomerulonephritis\u003c\/li\u003e\n\u003cli\u003eNovel immunosuppressive agents for glomerulonephritis\u003c\/li\u003e\n\u003cli\u003eAnd more…\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cstrong\u003eDate of Original Release:\u003c\/strong\u003e October 15, 2025\u003cbr\u003e\u003cstrong\u003eEstimated Time to Complete the Activity:\u003c\/strong\u003e 50.00 hours\u003cbr\u003e\u003ch3\u003eLearning Objectives\u003c\/h3\u003e\u003cbr\u003eUpon completion of this activity, participants will be able to:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eSummarize current\/recommended nephrology guidelines in clinical practice\u003c\/li\u003e\n\u003cli\u003eExplain the differential diagnosis of complex clinical presentations of patients with renal disorders\u003c\/li\u003e\n\u003cli\u003eIdentify\/integrate current therapeutic options for specific renal disorders\u003c\/li\u003e\n\u003cli\u003eReview and interpret up-to-date literature relevant to clinical practice\u003c\/li\u003e\n\u003cli\u003eDescribe pathophysiological mechanisms as they apply to management of renal disease\u003c\/li\u003e\n\u003cli\u003eSynthesize teachings to better performance on the ABIM Nephrology certification\/recertification examinations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eTarget Audience\u003c\/h3\u003e\u003cbr\u003eThe target audience for the” Intensive Review of Nephrology” Course is clinical and academic nephrologists, internists, pediatricians, and primary care physicians\/trainees preparing for ABIM nephrology certification\/recertification examinations and\/or seeking a comprehensive update in renal medicine and its subspecialties.\u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTopics:\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003cul\u003e\n\u003cli\u003eRenal Physiology for the Boards – \u003cem\u003eMelanie P. Hoenig, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eBasic Concepts of Immunology in Autoimmune Kidney Disease – \u003cem\u003eRamon Bonegio, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eRenal Pathology in 2025 – Part 1 – Nephritic Conditions – \u003cem\u003eHelmut G. Rennke, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eRenal Pathology in 2025 – Part 2 – Nephritic Syndrome – \u003cem\u003eAstrid Weins, MD, PhD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eUrine Sediment Analysis – \u003cem\u003eMartina M. McGrath, MB BCh\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003ePathogenesis, Diagnosis, and Treatment of IgA Nephropathy – \u003cem\u003eGerald B. Appel, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eMetabolic Management of Kidney Stones – \u003cem\u003eGary Curhan, MD, ScD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eKeynote – AI in Nephrology – \u003cem\u003eGirish N. Nadkarni, MD, MPH, CPH\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eTreating Lupus Nephritis in 2025 – New Guidelines, New Medications, and New Challenges – \u003cem\u003eGerald B. Appel, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eMembranous Nephropathy – \u003cem\u003eLaurence H. Beck, Jr., MD, PhD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eAnemia Management – Update and Best Practices – \u003cem\u003eBrona M. Moloney, MBBCH, BAO, MMSc\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eAcid-Base Disorders Part I – Anion Gap Metabolic Acidosis – \u003cem\u003eAlan S.L. Yu, MB, BChir\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eAcid-Base Disorders II – Non-Gap Acidosis and Metabolic Alkalosis – \u003cem\u003eAlan S.L. Yu, MB, Bchir\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eSodium Disorders – \u003cem\u003eDavid B. Mount, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003ePotassium Disorders – \u003cem\u003eDavid B. Mount, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eImportant New Trials in GN – \u003cem\u003eDavid B. Mount, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eGenetics and Kidney Disease – \u003cem\u003eFriedhelm Hildebrandt, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eUpdate on Polycystic Kidney Disease – \u003cem\u003eFouad T. Chebib, MD, FASN\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003ePediatric Nephrology – \u003cem\u003eMichael J.G. Somers, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eGenetics – How to Integrate It into Practice – \u003cem\u003eAna Onuchic-Whitford, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eDiagnosis and Treatment of ANCA-associated Vasculitis – \u003cem\u003eJohn L. Niles, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eWhy Do We Reject a Transplant? – \u003cem\u003eJamil R. Azzi, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eTransplant Immunosuppression for the Boards – \u003cem\u003eBrittany L. Schreiber, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eImmunological Assessment Pre and Post Transplant – \u003cem\u003eMelissa Y. Yeung, MD and Indira Guleria, PhD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eEarly Post-Transplant Management – \u003cem\u003eAnil K. Chandraker, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eEvaluation of the Living Donor Candidate – \u003cem\u003eKassem Safa, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eLate Loss of the Kidney Transplant – \u003cem\u003eRania Khedher El Fekih, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eInfections in Transplant Recipients – \u003cem\u003eBarbra M. Blair, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eMonitoring Kidney Transplant Patients – Beyond Creatinine – \u003cem\u003eJamil R. Azzi, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003ePre-Transplant Surgical Evaluation of Recipients – \u003cem\u003eRania Khedher El Fekih, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003ePoisonings and Intoxications – What a Nephrologist Needs to Know – \u003cem\u003eCharlotte E. Goldfine, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eLate Post-Transplant Medical Complications – \u003cem\u003eLeonardo V. Riella, MD, PhD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eHemolytic Uremic Syndrome (HUS) and Thrombotic Thrombocytopenic Purpura (TTP) – \u003cem\u003eJean M. Francis, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eGeriatric Nephrology – \u003cem\u003eErnest I. Mandel, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eCardio-Renal Syndrome – \u003cem\u003eFinnian R. McCausland, MB BCh, MMSc, FRCPI\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eManagement of Hypertension in CKD-Intensive or Standard Regimens – \u003cem\u003eRichard J. Glassock, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003ePrimary Aldosteronism – \u003cem\u003eAnand Vaidya, MD, MMSc\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eKeynote – Climate Change, Global Inequities, and the Kidney – \u003cem\u003eValerie A. Luyckx, MBBCh, MSc, PhD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eLiver and the Kidney – \u003cem\u003eAndrew S. Allegretti, MD, MSc\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003ePathophysiology of Acute Kidney Injury – \u003cem\u003eJoseph V. Bonventre, MD, PhD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eAcute Kidney Injury Syndromes – \u003cem\u003eAlice Sheridan, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eICU Nephrology and Continuous Renal Replacement Therapies – \u003cem\u003eDavid J.R. Steele, MB BCh\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eAcute Kidney Injury in Cancer – \u003cem\u003eRaad Chowdhury, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eParaprotein-Induced Kidney Injury – \u003cem\u003eRaad Chowdhury, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eTherapy of Focal and Segmental Glomerulosclerosis (FSGS) Lesions in 2025 – \u003cem\u003eRichard J. Glassock, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003ePathophysiology and Treatment of Diabetic Kidney Disease – \u003cem\u003eGearoid M. McMahon, MB BCh\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eAPOL1 and Kidney Disease – \u003cem\u003eOpeyemi Olabisi, MD, PhD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003ePatient Perspective – Dialysis Dosing – \u003cem\u003eModerators – J. Kevin Tucker, MD and Paul Moore; Dialysis Patients – Daphne Rhodes and Vanessa Evans\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eChronic Kidney Disease – Mineral and Bone Disease – \u003cem\u003eDavid Bushinsky, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eDialysis – A Case-Based Clinical Review and Update – \u003cem\u003eJ. Kevin Tucker, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eChronic Kidney Disease – Mineral and Bone Disease Case-Based Pearls – \u003cem\u003eDavid Bushinsky, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eChronic Kidney Disease Epidemiology – \u003cem\u003eGearoid M. McMahon, MB BCh\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eIntroduction to Peritoneal Dialysis – \u003cem\u003eJoanne M. Bargman, MD, FRCPC\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eComplications of Peritoneal Dialysis – \u003cem\u003eJoanne M. Bargman, MD, FRCPC\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eAcute Kidney Injury Related to Immune Checkpoint Inhibitors – \u003cem\u003eShruti Gupta, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eMesoamerican Nephropathy – \u003cem\u003eDavid J. Friedman, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eUltrasound for the Clinical Nephrologist – \u003cem\u003eAdina S. Voiculescu, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eDialysis Vascular Access – Assessment and Complications – \u003cem\u003eDirk M. Hentschel, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuestion and Answer Session – \u003cem\u003eFaculty\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eGlomerulonephritis – Questions \u0026amp; Answers Session – \u003cem\u003eGerald B. Appel, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eMust-Know Clinical Images in Nephrology – \u003cem\u003eAnnie Liu, DO, MPH, MS\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eElectrolytes and Acid-Base Practice for the Boards – Part 1 – \u003cem\u003eAlan S.L. Yu, MB, Bchir\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eElectrolytes and Acid-Base Practice for the Boards – Part 2 – \u003cem\u003eAlan S.L. Yu, MB, Bchir\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eChronic Kidney Disease in the Community – Leveraging Resources Effectively, Lessons Learned from KDSAP – \u003cem\u003eLi-Li Hsiao, MD, PhD, FACP\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eCOVID-19 Vaccination in Immunocompromised Patients – \u003cem\u003eAnn Woolley, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eUpdate on Renovascular Disease – \u003cem\u003eJoseph M. Garasic, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003ePre-Transplant Surgical Evaluation of Recipients – \u003cem\u003eSayeed Malek, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eImmunologic Basis of Kidney Disease – \u003cem\u003eVivek Kasinath, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eUse of Checkpoint Inhibitors in Kidney Transplant Recipients – \u003cem\u003eNaoka Murakami, MD, PhD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eInterstitial Nephritis – Overview for the Boards – \u003cem\u003eJulie M. Paik, MD, ScD, MPH\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eEthics in Nephrology – \u003cem\u003eValerie Luyckx, MD, MB BCh\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003ePregnancy and Renal Disease – \u003cem\u003eJessica Tangren, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eTransplant Cases – Board Review Practice – \u003cem\u003eMelissa Y. Yeung, MD and Edgar L. Milford, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eTransplant Board Review – \u003cem\u003eAnil K. Chandraker, MD\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eMust-Know Board Zebras – \u003cem\u003eEmily Robinson, MD, MPH\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eNephrology Board Review Practice 1 – \u003cem\u003eFinnian McCausland, MB BCh, MMSc, FRCPI\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eNephrology Board Review Practice 2 – \u003cem\u003eGearoid M. McMahon, MB BCh\u003c\/em\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e ","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954505093218,"sku":"MED-AMB04863","price":30.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Oakstone-Intensive-Review-of-Nephrology-2025-768x768-1.webp?v=1779378354","url":"https:\/\/meducourse.com\/products\/oakstone-intensive-review-of-nephrology-2025","provider":"Meducourse","version":"1.0","type":"link"}